Efficacy of α-blocker or 5-ARI Withdrawal to Continued Combination Therapy on the Maintenance of LUTS in Men With BPH

Last updated: August 21, 2021
Sponsor: Gangnam Severance Hospital
Overall Status: Active - Recruiting

Phase

3

Condition

Benign Prostatic Hyperplasia (Enlarged Prostate)

Prostate Disorders

Treatment

N/A

Clinical Study ID

NCT05023824
3-2020-0451
3-2020-0451
  • Ages 50-80
  • Male

Study Summary

The investigators compare the efficacy of alpha-blocker and 5-ARI withdrawal to continued combination therapy on the maintenance of LUTS and improvement of quality of life outcomes in men with benign prostatic hyperplasia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men aged ≥50 or <80 years AND
  • On combination therapy (alpha-blocker and 5-ARI) ≥12 months AND
  • IPSS score (≤30% decrease from baseline) AND
  • Prostate volume (≤35% decrease from baseline)

Exclusion

Exclusion Criteria:

  • Suspected prostate cancer (PSA density >0.15 ng/ml/cc) requiring specific management
  • On-going prostatitis or urinary retention
  • Acontractile detrusor
  • Neurogenic lower urinary tract dysfunction
  • Urethral stenosis
  • Patient unable or unwilling to provide written informed consent

Study Design

Total Participants: 300
Study Start date:
December 08, 2020
Estimated Completion Date:
December 07, 2023

Study Description

Benign Prostatic Hyperplasia (BPH) is the primary cause of lower urinary tract symptoms (LUTS). Combination therapy with an alpha-blocker and 5α reductase inhibitors (5-ARI) is the first-line treatment of BPH-related LUTS for the reduction of the size of the prostate and LUTS improvement. Combination therapy is tolerated well by most men; however, the incidence of adverse events is higher than with either therapy alone. In patients with improved LUTS following combination therapy, the aim of this study is based on the hypothesis that the withdrawal of either therapy will not increase the risk of LUTS aggravation while improving the quality of life.

The investigators plan a prospective, randomized, open-label, parallel trial, comparing alpha-blocker withdrawal and 5-ARI withdrawal to continued combination therapy. Treatments will be allocated in a 1:1:1 ratio, based on IPSS score (≤30% decrease from baseline) and prostate volume (≤35% decrease from baseline).

Connect with a study center

  • Gangnam Severance Hospital, Yonsei University College of Medicine

    Seoul, 135-720
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.